

# Marco Gambacciani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5006953/publications.pdf>

Version: 2024-02-01

203  
papers

7,403  
citations

47006

47  
h-index

66911

78  
g-index

207  
all docs

207  
docs citations

207  
times ranked

5495  
citing authors

#	ARTICLE	IF	CITATIONS
1	Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, s1-s66.	3.6	512
2	Body Weight, Body Fat Distribution, and Hormonal Replacement Therapy in Early Postmenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 414-417.	3.6	284
3	Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. <i>Climacteric</i> , 2013, 16, 316-337.	2.4	255
4	Phalangeal Osteosonogrammetry Study: Age-Related Changes, Diagnostic Sensitivity, and Discrimination Power. <i>Journal of Bone and Mineral Research</i> , 2000, 15, 1603-1614.	2.8	204
5	"Controversial Issues in Climacteric Medicine" Series 3rd Pisa Workshop "HRT in Climacteric and Aging Brain" Under the Auspices of the International Menopause Society, Pisa, Italy, 15-18 March 2003. <i>Maturitas</i> , 2003, 46, 7-26.	2.4	202
6	Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. <i>Climacteric</i> , 2011, 14, 302-320.	2.4	176
7	GnRH Release from the Mediobasal Hypothalamus: in vitro Inhibition by Corticotropin-Releasing Factor. <i>Neuroendocrinology</i> , 1986, 43, 533-536.	2.5	175
8	IMS Updated Recommendations on postmenopausal hormone therapy. <i>Climacteric</i> , 2007, 10, 181-194.	2.4	155
9	Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. <i>European Heart Journal</i> , 2007, 28, 2028-2040.	2.2	147
10	Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy. <i>Maturitas</i> , 2001, 39, 125-132.	2.4	145
11	Vaginal erbium laser: the second-generation thermotherapy for the genitourinary syndrome of menopause. <i>Climacteric</i> , 2015, 18, 757-763.	2.4	137
12	EMAS position statement: Managing women with premature ovarian failure. <i>Maturitas</i> , 2010, 67, 91-93.	2.4	128
13	Laser therapy for the restoration of vaginal function. <i>Maturitas</i> , 2017, 99, 10-15.	2.4	102
14	Hormonal influence on the central nervous system. <i>Maturitas</i> , 2002, 43, 11-17.	2.4	100
15	Featured Editorial Hormone replacement therapy and the prevention of postmenopausal osteoporosis. <i>Przegląd Menopauzalny</i> , 2014, 4, 213-220.	1.3	100
16	Long-term effects of vaginal erbium laser in the treatment of genitourinary syndrome of menopause. <i>Climacteric</i> , 2018, 21, 148-152.	2.4	100
17	Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper. <i>Pharmacological Research</i> , 2018, 134, 51-60.	7.1	98
18	The effect of menopause on blood lipid and lipoprotein levels. <i>Atherosclerosis</i> , 1999, 147, 147-153.	0.8	95

#	ARTICLE	IF	CITATIONS
19	EMAS position statement: Vitamin D and postmenopausal health. <i>Maturitas</i> , 2012, 71, 83-88.	2.4	95
20	Climacteric modifications in body weight and fat tissue distribution. <i>Climacteric</i> , 1999, 2, 37-44.	2.4	93
21	Pulsatile Gonadotropin-Releasing Hormone Release from the Human Mediobasal Hypothalamus in vitro: Opiate Receptor-Mediated Suppression. <i>Neuroendocrinology</i> , 1989, 49, 150-156.	2.5	86
22	Vasomotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases?. <i>Climacteric</i> , 2017, 20, 306-312.	2.4	80
23	Evidence that Estrogens Inhibit LH Secretion through Opioids in Postmenopausal Women Using Naloxone. <i>Neuroendocrinology</i> , 1984, 39, 60-63.	2.5	77
24	Vaginal erbium laser as second-generation thermotherapy for the genitourinary syndrome of menopause: a pilot study in breast cancer survivors. <i>Menopause</i> , 2017, 24, 316-319.	2.0	77
25	Effect of climacteric transition and hormone replacement therapy on body weight and body fat distribution. <i>Gynecological Endocrinology</i> , 2006, 22, 145-150.	1.7	76
26	Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. <i>Climacteric</i> , 2008, 11, 108-123.	2.4	76
27	Effects of low-dose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women. <i>Maturitas</i> , 2003, 44, 157-163.	2.4	75
28	Determinants of age at menopause in Italy: results from a large cross-sectional study. <i>Maturitas</i> , 2000, 34, 119-125.	2.4	71
29	Ultrasonographic bone characteristics during normal pregnancy: Longitudinal and cross-sectional evaluation. <i>American Journal of Obstetrics and Gynecology</i> , 1995, 173, 890-893.	1.3	67
30	Hormone replacement therapy and endometrial, ovarian and colorectal cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2003, 17, 139-147.	4.7	65
31	Menopause and aging, quality of life and sexuality. <i>Climacteric</i> , 2007, 10, 88-96.	2.4	63
32	Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women. <i>Maturitas</i> , 1997, 28, 75-81.	2.4	57
33	Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women. <i>American Journal of Obstetrics and Gynecology</i> , 2001, 185, 1180-1185.	1.3	57
34	Intrinsic Pulsatility of Luteinizing Hormone Release from the Human Pituitary in vitro. <i>Neuroendocrinology</i> , 1987, 45, 402-406.	2.5	56
35	Management of postmenopausal osteoporosis and the prevention of fractures. <i>Panminerva Medica</i> , 2014, 56, 115-31.	0.8	56
36	Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women. <i>Journal of Endocrinological Investigation</i> , 1993, 16, 333-337.	3.3	55

#	ARTICLE	IF	CITATIONS
37	Hormone replacement therapy in perimenopausal women with a low dose oral contraceptive preparation: Effects on bone mineral density and metabolism. <i>Maturitas</i> , 1994, 19, 125-131.	2.4	55
38	Longitudinal evaluation of perimenopausal vertebral bone loss: effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism. <i>Obstetrics and Gynecology</i> , 1994, 83, 392-6.	2.4	55
39	Rationale and design for the Vaginal Erbium Laser Academy Study (VELAS): an international multicenter observational study on genitourinary syndrome of menopause and stress urinary incontinence. <i>Climacteric</i> , 2015, 18, 43-48.	2.4	54
40	INTRINSIC PULSATILITY OF ACTH RELEASE FROM THE HUMAN PITUITARY IN VITRO. <i>Clinical Endocrinology</i> , 1987, 26, 557-563.	2.4	53
41	Assessment of the QoL in Italian menopausal women: comparison between HRT users and non-users. <i>Maturitas</i> , 2002, 42, 267-280.	2.4	53
42	Factors associated with climacteric symptoms in women around menopause attending menopause clinics in Italy. <i>Maturitas</i> , 2005, 52, 181-189.	2.4	53
43	Management of cardiovascular risk in the perimenopausal women: a consensus statement of European cardiologists and gynecologists. <i>Climacteric</i> , 2007, 10, 508-526.	2.4	51
44	Effects of low-dose, continuous combined hormone replacement therapy on sleep in symptomatic postmenopausal women. <i>Maturitas</i> , 2005, 50, 91-97.	2.4	50
45	The relative contributions of menopause and aging to postmenopausal vertebral osteopenia.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1993, 77, 1148-1151.	3.6	49
46	Guidelines for hormone treatment of women in the menopausal transition and beyondPosition Statement by the Executive Committee of the International Menopause Society(Revised October 15,) Tj ETQq0 0 OmgBT /Overlock 10 Tf		
47	EMAS position statement: Managing the menopause in the context of coronary heart disease. <i>Maturitas</i> , 2011, 68, 94-97.	2.4	49
48	Longitudinal evaluation of perimenopausal bone loss: Effects of different low dose oral contraceptive preparations on bone mineral density. <i>Maturitas</i> , 2006, 54, 176-180.	2.4	48
49	Hormone replacement therapy: the perspectives for the 21st century. <i>Maturitas</i> , 1999, 32, 11-17.	2.4	47
50	Clinical usefulness of endometrial screening by ultrasound in asymptomatic postmenopausal women. <i>Maturitas</i> , 2004, 48, 421-424.	2.4	45
51	EMAS position statement: Managing obese postmenopausal women. <i>Maturitas</i> , 2010, 66, 323-326.	2.4	45
52	The relative contributions of menopause and aging to postmenopausal vertebral osteopenia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1993, 77, 1148-1151.	3.6	45
53	EMAS position statement: Managing the menopause in women with a past history of endometriosis. <i>Maturitas</i> , 2010, 67, 94-97.	2.4	42
54	The Effects of the Gabaergic Drug, Sodium Valproate, on Prolactin Secretion in Normal and Hyperprolactinemic Subjects*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1982, 54, 485-489.	3.6	41

#	ARTICLE	IF	CITATIONS
55	GnRH Release from the Mediobasal Hypothalamus. <i>Neuroendocrinology</i> , 1986, 42, 181-183.	2.5	40
56	Cardiovascular disease and hormone replacement therapy. <i>Climacteric</i> , 2000, 3, 233-240.	2.4	40
57	Longitudinal Evaluation of Perimenopausal Femoral Bone Loss: Effects of a Low-Dose Oral Contraceptive Preparation on Bone Mineral Density and Metabolism. <i>Osteoporosis International</i> , 2000, 11, 544-548.	3.1	40
58	Neuroendocrine and clinical effects of transdermal 17 $\beta$ -estradiol in postmenopausal women. <i>Maturitas</i> , 1991, 13, 283-296.	2.4	39
59	The relative contributions of menopause and aging to postmenopausal reduction in intervertebral disk height. <i>Climacteric</i> , 2007, 10, 298-305.	2.4	39
60	Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. <i>Maturitas</i> , 2008, 59, 2-6.	2.4	39
61	EMAS position statement: Managing menopausal women with a personal or family history of VTE. <i>Maturitas</i> , 2011, 69, 195-198.	2.4	38
62	Short-term effect of vaginal erbium laser on the genitourinary syndrome of menopause. <i>Minerva Ginecologica</i> , 2015, 67, 97-102.	0.8	38
63	Lack of any estrogenic effect of ipriflavone in postmenopausal women. <i>Journal of Endocrinological Investigation</i> , 1992, 15, 755-761.	3.3	36
64	Inhibitory Effect of the Dopamine Agonist Bromocriptine on the Postcastration Gonadotropin Rise in Women*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1981, 53, 530-535.	3.6	35
65	Bone loss in perimenopausal women: a longitudinal study. <i>Maturitas</i> , 1994, 18, 191-197.	2.4	35
66	Comparison of effects of 3 mg drospirenone plus 20 $\mu$ g ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2010, 94, 1793-1798.	1.0	35
67	Ipriflavone prevents the bone mass reduction in premenopausal women treated with gonadotropin hormone-releasing hormone agonists. <i>Bone and Mineral</i> , 1994, 26, 19-26.	1.9	34
68	Vaginal atrophy across the menopausal age: results from the ANGEL study. <i>Climacteric</i> , 2019, 22, 85-89.	2.4	33
69	Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society. <i>Maturitas</i> , 2022, 163, 1-14.	2.4	33
70	Hormone replacement therapy: the benefits in tailoring the regimen and dose. <i>Maturitas</i> , 2001, 40, 195-201.	2.4	32
71	Chronic Bromocriptine Administration Restores Luteinizing Hormone Response to Naloxone in Postmenopausal Women. <i>Neuroendocrinology</i> , 1988, 47, 159-163.	2.5	31
72	Reduction in the size of prolactin-producing pituitary tumor after Cabergoline * administration. <i>Fertility and Sterility</i> , 1989, 52, 412-415.	1.0	31

#	ARTICLE	IF	CITATIONS
73	Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. <i>Maturitas</i> , 2005, 50, 305-311.	2.4	31
74	Hormone replacement therapy and cancer. <i>Climacteric</i> , 2001, 4, 181-193.	2.4	30
75	Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium. <i>Bone and Mineral</i> , 1992, 19, S49-S56.	1.9	29
76	Controversial issues in climacteric medicine II. <i>Maturitas</i> , 2001, 40, 117-130.	2.4	29
77	Dose-Related Prolactin Inhibitory Effect of the New Long-Acting Dopamine Receptor Agonist Cabergoline in Normal Cycling, Puerperal, and Hyperprolactinemic Women*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1987, 65, 541-545.	3.6	28
78	Dexamethasone Reduces the Postcastration Gonadotropin Rise in Women<sup>*</sup>. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1987, 65, 237-241.	3.6	28
79	Clinical and metabolic effects of drospirenoneâ€“estradiol in menopausal women: a prospective study. <i>Climacteric</i> , 2011, 14, 18-24.	2.4	28
80	Postmenopausal osteoporosis and hormone replacement therapy. <i>Minerva Medica</i> , 2004, 95, 507-20.	0.9	28
81	Pulsatile Luteinizing Hormone Release in Postmenopausal Women: Effect of Chronic Bromocriptine Administration*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1987, 65, 465-468.	3.6	27
82	Postmenopausal osteoporosis management. <i>Current Opinion in Obstetrics and Gynecology</i> , 2000, 12, 189-197.	2.0	27
83	Effects of the dopamine antagonist veralipride on hot flashes and luteinizing hormone secretion in postmenopausal women. <i>Obstetrics and Gynecology</i> , 1988, 72, 688-92.	2.4	27
84	Vasomotor symptoms and cardiovascular risk. <i>Climacteric</i> , 2009, 12, 32-35.	2.4	26
85	Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 85-92.	1.5	26
86	Hormone replacement therapy and prevention of chronic conditions. <i>Climacteric</i> , 2019, 22, 303-306.	2.4	26
87	Effects of different dopamine agonists and antagonists on post-menopausal hot flashes. <i>Maturitas</i> , 1986, 8, 229-237.	2.4	25
88	Bone density changes in postmenopausal women with the administration of ipriflavone alone or in association with low-dose ERT. <i>Gynecological Endocrinology</i> , 1997, 11, 289-293.	1.7	25
89	Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate. <i>Maturitas</i> , 2002, 41, 299-311.	2.4	25
90	Female urinary stress incontinence. <i>Climacteric</i> , 2015, 18, 30-36.	2.4	25

#	ARTICLE	IF	CITATIONS
91	Postmenopausal femur bone loss: effects of a low dose hormone replacement therapy. <i>Maturitas</i> , 2003, 45, 175-183.	2.4	24
92	Controversial issues in climacteric medicine IV - Postmenopausal osteoporosis: therapeutic options. <i>Climacteric</i> , 2005, 8, 99-109.	2.4	24
93	Effects of continuous and cyclic nasal calcitonin administration in ovariectomized women. <i>Maturitas</i> , 1992, 15, 225-232.	2.4	23
94	Quantitative ultrasound (QUS) of bone in the management of postmenopausal women. <i>Maturitas</i> , 2004, 47, 139-149.	2.4	22
95	Effect of an oral contraceptive containing 30 µg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention. <i>Contraception</i> , 2007, 76, 190-194.	1.5	22
96	Robust normal mixtures for financial portfolio allocation. <i>Econometrics and Statistics</i> , 2017, 3, 91-111.	0.8	22
97	Safety of vaginal erbium laser: A review of 113,000 patients treated in the past 8 years. <i>Climacteric</i> , 2020, 23, S28-S32.	2.4	22
98	Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms – an update on the evidence. <i>Climacteric</i> , 2021, 24, 109-119.	2.4	22
99	INFLUENCE OF OESTRADIOL AND PROGESTERONE ON PULSATILE LH SECRETION IN POSTMENOPAUSAL WOMEN. <i>Clinical Endocrinology</i> , 1989, 31, 541-550.	2.4	21
100	Treatment of postmenopausal vertebral osteopenia with monofluorophosphate: A long-term calcium-controlled study. <i>Osteoporosis International</i> , 1995, 5, 467-471.	3.1	21
101	Validation of Italian version of the Women's Health Questionnaire: assessment of quality of life of women from the general population and those attending menopause centers. <i>Climacteric</i> , 2002, 5, 70-77.	2.4	21
102	Effects of Oral Contraceptives on Bone Mineral Density. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2004, 3, 191-196.	1.8	21
103	Restoration of Luteinizing Hormone Response to Naloxone in Postmenopausal Women by Chronic Administration of the Antidopaminergic Drug Veralipride*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1988, 66, 964-967.	3.6	20
104	Clinical relevance of the HERS trial. <i>Lancet, The</i> , 2002, 360, 641.	13.7	19
105	Dydrogesterone does not reverse the effects of estradiol on endothelium-dependant vasodilation in postmenopausal women: a randomised clinical trial. <i>Maturitas</i> , 2002, 43, 117-123.	2.4	19
106	A longitudinal evaluation of the effect of two doses of tibolone on bone density and metabolism in early postmenopausal women. <i>Gynecological Endocrinology</i> , 2004, 18, 9-16.	1.7	19
107	The HRT misuse and osteoporosis epidemic: a possible future scenario. <i>Climacteric</i> , 2007, 10, 273-275.	2.4	19
108	EMAS position statement: Bone densitometry screening for osteoporosis. <i>Maturitas</i> , 2011, 68, 98-101.	2.4	17

#	ARTICLE	IF	CITATIONS
109	EMAS clinical guide: Selective estrogen receptor modulators for postmenopausal osteoporosis. <i>Maturitas</i> , 2012, 71, 194-198.	2.4	17
110	What women think about menopause: An Italian survey. <i>Maturitas</i> , 2021, 147, 47-52.	2.4	17
111	Some properties of a purinergic receptor solubilized from human uterus membranes. <i>FEBS Letters</i> , 1984, 172, 335-338.	2.8	16
112	Hormone Replacement Therapy in Perimenopause. <i>Menopause</i> , 1999, 6, 43-48.	2.0	16
113	Sociodemographic and clinical factors associated with HRT use in women attending menopause clinics in Italy. <i>Climacteric</i> , 2000, 3, 241-247.	2.4	16
114	Long-term treatment with $\alpha$ -lipoic acid and myo-inositol positively affects clinical and metabolic features of polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2020, 36, 152-155.	1.7	16
115	Reflections and recommendations on the COVID-19 pandemic: Should hormone therapy be discontinued?. <i>Maturitas</i> , 2020, 138, 76-77.	2.4	16
116	GnRH stimulates acth and immunoreactive $\beta$ -endorphin release from the rat pituitary. <i>Life Sciences</i> , 1988, 43, 755-760.	4.3	15
117	A personal initiative for women's health: to challenge the Women's Health Initiative. <i>Gynecological Endocrinology</i> , 2002, 16, 255-257.	1.7	15
118	Pulsatile $\beta$ -endorphin release from the human pituitary in vitro. <i>Gynecological Endocrinology</i> , 1988, 2, 1-10.	1.7	14
119	Effects of a new estrogen/progestin combination in the treatment of postmenopausal syndrome. <i>Maturitas</i> , 1995, 22, 115-120.	2.4	14
120	Practical recommendations for hormone replacement therapy in the peri- and postmenopause. <i>Climacteric</i> , 2004, 7, 210-216.	2.4	14
121	Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists. <i>Calcified Tissue International</i> , 1997, 61, S15-S18.	3.1	13
122	HRT in the third millennium. <i>Maturitas</i> , 2001, 38, S49-S55.	2.4	13
123	The missing R. <i>Gynecological Endocrinology</i> , 2003, 17, 91-94.	1.7	13
124	Postmenopausal Bone Loss of the Proximal Femur. <i>Menopause</i> , 1995, 2, 169-174.	2.0	12
125	Low-dose hormone replacement therapy: effects on bone. <i>Climacteric</i> , 2002, 5, 135-139.	2.4	12
126	The study with a million women (and hopefully fewer mistakes). <i>Gynecological Endocrinology</i> , 2003, 17, 359-362.	1.7	12



#	ARTICLE	IF	CITATIONS
127	Tailored hormonal approach in women with premature ovarian insufficiency. <i>Climacteric</i> , 2020, 23, 3-8.	2.4	12
128	Sexual function after vaginal erbium laser: the results of a large, multicentric, prospective study. <i>Climacteric</i> , 2020, 23, S24-S27.	2.4	12
129	Joint recommendations for the diagnosis and treatment of vulvo-vaginal atrophy in women in the peri- and post-menopausal phases from the Società Italiana per la Menopausa (SIM) and the Società Italiana della Terza Et� (SIGITE). <i>Minerva Ginecologica</i> , 2019, 71, 345-352.	0.8	12
130	Hormone replacement therapy in climacteric and aging brain. <i>Climacteric</i> , 2003, 6, 188-203.	2.4	11
131	EMAS position statement: Managing the menopause in women with epilepsy. <i>Maturitas</i> , 2010, 66, 327-328.	2.4	11
132	Menopause and hormone replacement therapy: the 2017 Recommendations of the Italian Menopause Society. <i>Minerva Obstetrics and Gynecology</i> , 2018, 70, 27-34.	1.0	11
133	Regulation of body temperature in postmenopausal women: Interactions between bromocriptine and the endogenous opioid system. <i>Life Sciences</i> , 1989, 44, 1395-1402.	4.3	10
134	Efficacy on climacteric symptoms of a continuous combined regimen of 1�mg 17�-estradiol and trimegestone versus two regimens containing 1 or 2�mg 17�-estradiol and norethisterone acetate. <i>Gynecological Endocrinology</i> , 2005, 21, 65-73.	1.7	10
135	Recommendations on the management of fragility fracture risk in women younger than 70 years. <i>Gynecological Endocrinology</i> , 2012, 28, 770-786.	1.7	10
136	Effects of ospemifene on bone in postmenopausal women. <i>Climacteric</i> , 2019, 22, 442-447.	2.4	9
137	Recommendations on menopausal hormone replacement therapy. <i>Minerva Ginecologica</i> , 2020, 71, 395-403.	0.8	9
138	Sex Steroids Modulate Prolactin Response to Naloxone in Postmenopausal Women. <i>Neuroendocrinology</i> , 1985, 41, 138-141.	2.5	8
139	Prevention of Postmenopausal Bone Loss and Endometrial Responses during a Two Year Prospective Study with Transdermal 17�-Estradiol and Oral Medroxyprogesterone Acetate. <i>Annals of the New York Academy of Sciences</i> , 1991, 622, 302-306.	3.8	8
140	Effect of hormone replacement therapy with the anti-mineralocorticoid progestin Drospirenone compared to tibolone on endothelial function and central haemodynamics in post-menopausal women. <i>International Journal of Cardiology</i> , 2017, 227, 217-221.	1.7	8
141	Genitourinary syndrome of menopause (GSM) and laser VEL: a review. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2020, 41, .	0.7	8
142	Can estrogens protect against COVID-19? The COVID-19 puzzling and gender medicine. <i>Minerva Ginecologica</i> , 2020, 72, 178-179.	0.8	8
143	Dose-related effects of �-amino �-hydroxy butyric acid (GABOB) infusion on growth hormone secretion in normal women. <i>Journal of Endocrinological Investigation</i> , 1982, 5, 101-106.	3.3	7
144	Effects of the antidopaminergic drug veralipride on LH and PRL secretion in postmenopausal women. <i>Journal of Endocrinological Investigation</i> , 1989, 12, 295-301.	3.3	7

#	ARTICLE	IF	CITATIONS
145	Quantitative Bone Ultrasonometry in Climacteric Women. <i>Journal of Clinical Densitometry</i> , 1998, 1, 303-308.	1.2	7
146	New HRT Options for the Treatment of Menopausal Symptoms and the Maintenance of Quality of Life in Postmenopausal Women. <i>Endocrine</i> , 2004, 24, 231-238.	2.2	7
147	HRT misuse and the osteoporosis epidemic. <i>Climacteric</i> , 2012, 15, 10-11.	2.4	7
148	Viewing symptoms associated with Vulvovaginal Atrophy (VVA)/Genitourinary syndrome of menopause (GSM) through the estro-androgenic lens â€” Cluster analysis of a web-based Italian survey among women over 40. <i>Maturitas</i> , 2020, 140, 72-79.	2.4	7
149	Short-term effects of an erbium/neodymium laser combination in superficial dyspareunia: a pilot study. <i>Climacteric</i> , 2022, 25, 208-211.	2.4	7
150	Evidence of Specific Benzodiazepine Binding to Myometrial Membrane Preparations From Human Pregnant Uterus. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 1986, 65, 341-343.	2.8	6
151	Estrogens and women's health: a scary or a fairy tale?. <i>Gynecological Endocrinology</i> , 2004, 18, 175-178.	1.7	6
152	Homocysteine, menopause and cardiovascular disease. <i>Menopause International</i> , 2007, 13, 23-26.	1.6	6
153	Menopause and related problems. <i>Minerva Medica</i> , 2007, 98, 191-201.	0.9	6
154	Examining vaginal and vulvar health and sexual dysfunction in patients with interstitial cystitis (UNICORN-1 study). <i>International Urogynecology Journal</i> , 2022, 33, 2493-2499.	1.4	6
155	Autonomous gonadotropin release from the human pituitary in vitro and factors influencing this secretion. <i>Gynecological Endocrinology</i> , 1994, 8, 265-275.	1.7	5
156	Prospective evaluation of calcium and estrogen administration on bone mass and metabolism after ovariectomy. <i>Gynecological Endocrinology</i> , 1995, 9, 131-135.	1.7	5
157	Italian position statement on hormone replacement therapy following the National Conference on Menopause and Hormone Replacement Therapy, Villa Tuscolana, Frascati (Rome), May 8â€”9, 2007. <i>Gynecological Endocrinology</i> , 2007, 23, 436-444.	1.7	5
158	&lt;p&gt;Contraception with estradiol valerate and dienogest: adherence to the method&lt;/p&gt;. <i>Open Access Journal of Contraception</i> , 2019, Volume 10, 1-6.	1.4	5
159	Er:YAG laser in hysterectomized women with stress urinary incontinence: a VELA retrospective cohort, non-inferiority study. <i>Climacteric</i> , 2020, 23, S18-S23.	2.4	5
160	Low-dose hormone replacement therapy: effects on bone. <i>Climacteric</i> , 2002, 5, 135-139.	2.4	5
161	Hormone replacement therapy in perimenopause: effect of a low dose oral contraceptive preparation on bone quantitative ultrasound characteristics. <i>Menopause</i> , 1999, 6, 43-8.	2.0	5
162	Cyclic-combined Conjugated Estrogens and Dydrogesterone in the Treatment of Postmenopausal Syndrome. <i>Menopause</i> , 1995, 2, 19???26.	2.0	4

#	ARTICLE	IF	CITATIONS
163	The osteoporosis dilemma. <i>Gynecological Endocrinology</i> , 2004, 18, 59-61.	1.7	4
164	The Xmas present for women's health: a strike to osteoporosis prevention. <i>Maturitas</i> , 2004, 48, 9-11.	2.4	4
165	The latest elaboration of the Women's Health Initiative data on hormone replacement therapy and cardiovascular disease in postmenopausal women. <i>Gynecological Endocrinology</i> , 2007, 23, 183-185.	1.7	4
166	Erbium laser in gynecology: aims, aspirations and action points. <i>Climacteric</i> , 2015, 18, 2-3.	2.4	4
167	Validation of Italian version of the Women's Health Questionnaire: assessment of quality of life of women from the general population and those attending menopause centers. <i>Climacteric</i> , 2002, 5, 70-7.	2.4	4
168	Hormone replacement therapy: who should be treated?. <i>Minerva Ginecologica</i> , 2015, 67, 249-55.	0.8	4
169	The sound of an International anti-HRT herald. <i>Maturitas</i> , 2003, 46, 105-106.	2.4	3
170	Letters to the Editor. <i>Menopause</i> , 2003, 10, 266-267.	2.0	3
171	Risk Identification of Osteoporosis in Postmenopausal Women by a Simple Algorithm Based on Ultrasound Densitometry and Body Mass Index. <i>Journal of Clinical Densitometry</i> , 2008, 11, 412-416.	1.2	3
172	The relative contributions of menopause and aging to postmenopausal osteoporosis. <i>Climacteric</i> , 2020, 23, 105-105.	2.4	3
173	Low-dose hormone replacement therapy: effects on bone. <i>Climacteric</i> , 2002, 5, 135-9.	2.4	3
174	A personal initiative for women's health: to challenge the Women's Health Initiative. <i>Gynecological Endocrinology</i> , 2002, 16, 255-7.	1.7	3
175	The missing R. <i>Gynecological Endocrinology</i> , 2003, 17, 91-4.	1.7	3
176	Hormone replacement therapy in climacteric and aging brain. International Menopause Society Expert Workshop, 15-18 March 2003, Pisa, Italy. <i>Climacteric</i> , 2003, 6, 188-203.	2.4	3
177	Adrenal function under long-term raloxifene administration. <i>Gynecological Endocrinology</i> , 2003, 17, 159-168.	1.7	3
178	Validation of Italian version of the Women's Health Questionnaire: assessment of quality of life of women from the general population and those attending menopause centers. <i>Climacteric</i> , 2002, 5, 70-77.	2.4	3
179	From the challenge to the reassessment of the Women's Health Initiative: A personal initiative for women's health. <i>Gynecological Endocrinology</i> , 2006, 22, 115-116.	1.7	2
180	Comments on Preti et al: "The clinical role of LASER for vulvar and vaginal treatments in gynecology and female urology: An ICS/ISSVD best practice consensus document". <i>Neurourology and Urodynamics</i> , 2019, 38, 2010-2011.	1.5	2

#	ARTICLE	IF	CITATIONS
181	The effect of vulvovaginal atrophy on women's quality of life from an Italian cohort of the EVES study. <i>Journal of Obstetrics and Gynaecology</i> , 2020, 40, 512-519.	0.9	2
182	Re: Vaginal Er:YAG laser application in the menopausal ewe model: a randomised estrogen and sham-controlled trial. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, 128, 1099-1100.	2.3	2
183	The Effects of Acute and Chronic Administration of Salmon Calcitonin as Nasal Spray in Ovariectomized Women. <i>Annals of the New York Academy of Sciences</i> , 1990, 592, 453-456.	3.8	1
184	Identification of osteoporosis risk in postmenopausal women by the combined use of ultrasounds and clinical factors. <i>Fertility and Sterility</i> , 2003, 80, 15-16.	1.0	1
185	Vasomotor symptoms and negative affect. <i>Menopause</i> , 2011, 18, 1265-1266.	2.0	1
186	Pelvic Floor, Urinary Problems and the Menopause. , 2020, , 112-123.		1
187	Laser Treatment for Vulvovaginal Atrophy. , 2019, , 205-210.		1
188	Disappearance of opioid control of LH secretion in short term ovariectomized women. <i>Journal of Endocrinological Investigation</i> , 1985, 8 Suppl 2, 41-6.	3.3	1
189	Controversial issues in climacteric medicine III: Hormone replacement therapy in climacteric and aging brain. <i>Gynecological Endocrinology</i> , 2003, 17, 363-378.	1.7	0
190	Estro-progestinici in menopausa: benefici e rischi. <i>L Endocrinologo</i> , 2004, 5, 104-110.	0.0	0
191	The Return of Hormonal Therapy. <i>Women's Health</i> , 2007, 3, 421-422.	1.5	0
192	Author's reply. <i>Climacteric</i> , 2018, 21, 515-516.	2.4	0
193	Managing vulvovaginal atrophy after breast cancer. <i>Post Reproductive Health</i> , 2019, 25, 167-168.	0.9	0
194	Light the way for women's health. <i>Climacteric</i> , 2020, 23, S3-S3.	2.4	0
195	The VELA experience: a strategic format. <i>Climacteric</i> , 2020, 23, S4-S5.	2.4	0
196	Oral Contraceptive Use and Risk of Low Bone Density in Women Attending Menopause Clinics in Italy. <i>Medical Science Symposia Series</i> , 2002, , 239-242.	0.0	0
197	Effects of Oral Contraceptive Preparation on Bone Health. , 2006, , 177-183.		0
198	Perimenopausal Changes in Body Weight, Body Fat Distribution and Hormonal Replacement Therapy. <i>Medical Science Symposia Series</i> , 1997, , 61-67.	0.0	0

#	ARTICLE	IF	CITATIONS
199	Re: Vaginal Er:YAG laser application in the menopausal ewe model: a randomised estrogen and sham-controlled trial. (First comment on BJOG-20-1426.R2)., 0, , .		0
200	Progesterone to treat vasomotor symptoms. Climacteric, 2012, 15, 501-2.	2.4	0
201	A personal initiative for women's health: to challenge the Women's Health Initiative. Gynecological Endocrinology, 2002, 16, 255-257.	1.7	0
202	The missing R. Gynecological Endocrinology, 2003, 17, 91-94.	1.7	0
203	Hormone replacement therapy in climacteric and aging brain. Climacteric, 2003, 6, 188-203.	2.4	0